Marketing professionals in Pharmaceuticals
Oncology marketing titles at Amgen, Merck, Pfizer and Novartis sit alongside neuropsychiatry and ADHD brands at Acadia Pharmaceuticals and Otsuka, brands such as CIBINQO and EUCRISA at Pfizer, and biologics in Europe at Dr. Reddy's Laboratories. Two hold or have held launch lead titles, so the group suits a brand team planning a launch, weighing US against global roles, or working with payers and field teams.
Professionals to explore
Carolyn Hobbs
LinkedInExperience: Executive Director Nuplazid Neuropsychiatry Franchise Marketing · Acadia Pharmaceuticals
Carolyn Hobbs is Executive Director Nuplazid Neuropsychiatry Franchise Marketing at Acadia Pharmaceuticals (since 2023) and was Senior Director Professional Marketing (2020–2023) and Director Commercial Planning & Strategy (2019–2020) there. Carolyn was New Product Planning Lead at AnaptysBio (2018–2019) and Senior Director, Marketing and Consultant at Natera (2017–2018), and lists CNS, inflammation and immunology, cardiovascular, endocrinology and rare disease among therapeutic areas. Franchise marketing for a neuropsychiatry brand fits Carolyn.
Is this you? Claim your profile and get paid for calls.
Chris Morrison, Pharm.D.
LinkedInExperience: Global Marketing Director, CIBINQO & EUCRISA STAQUIS · Pfizer
Chris Morrison has been Global Marketing Director, CIBINQO & EUCRISA STAQUIS at Pfizer since 2022, and was US Marketing Director, CIBINQO & LITFULO (2020–2022) and US Marketing Director, EUCRISA (2018–2021) there. At Allergan (formerly Forest Laboratories and Actavis), Chris was Senior Product Manager, MONUROL (2017–2018) and Senior Product Manager, AVYCAZ (2016–2018). Chris cites results for 10 different brands across US and global markets, a fit for questions on moving a brand from US to global strategy.
Is this you? Claim your profile and get paid for calls.
Delphine Sengun
LinkedInExperience: Global Marketing Director, IMDELLTRA · Amgen
Delphine Sengun is Global Marketing Director, IMDELLTRA at Amgen (since 2026), after Global Marketing Senior Manager, Oncology Early Pipeline there (2024–2026). Delphine was Product Marketing Manager, TEPEZZA (Horizon Therapeutics acquired by Amgen, October 2023) at Amgen (2023–2024), and at Horizon held Product Marketing Manager, TEPEZZA (Commercial Leadership Program) (2023) and Manager, Strategy & Portfolio Management (Commercial Leadership Program) (2022–2023). Moving from early pipeline to a global brand fits questions on readying an oncology asset for global launch.
Is this you? Claim your profile and get paid for calls.
Denise Barrett Quigley
LinkedInExperience: Marketing Director · NS Pharma, Inc.
Denise Barrett Quigley has been Marketing Director at NS Pharma, Inc. since 2020 and worked in Payer Marketing at Pfizer (2019). At Otsuka Pharmaceutical Companies (U.S.), Denise was Marketing Director, Medical Device Division (2015–2019), Director, Customer and Channel Marketing (2014–2015) and Senior Product Manger, HCP Personal Promotion, Abilify Maintena (2012–2014). Denise describes launch, portfolio and brand work across rare disease, specialty and oncology, so payer and rare disease launch questions fit.
Is this you? Claim your profile and get paid for calls.
Hannah Bogardus
LinkedInExperience: Director, US Marketing - Oncology · Pfizer
Hannah Bogardus is Director, US Marketing - Oncology at Pfizer (since 2025) and was Director, US Marketing - Inflammation & Immunology (2024–2025), Senior Manager, US Marketing - Inflammation & Immunology (2022–2024), Manager, Marketing Rotational Program (2020–2022) and Marketing Summer Associate - Global Rare Disease (2019) there. The Inflammation & Immunology work included VELSIPITY HCP strategy, a fit for questions on HCP strategy and field coordination for a US brand.
Is this you? Claim your profile and get paid for calls.
Helga Lu
LinkedInExperience: Marketing Director · Daiichi Sankyo (India)
Helga Lu has been Marketing Director at Daiichi Sankyo (India) since 2022, a role covering ADC product management, after Marketing Director, Solid Tumor at Novartis (2021–2022). At AstraZeneca, Helga was Associate Marketing Director, ADC product lifecycle management (2020–2021), Associate Marketing Director, BC TA (2019–2020) and Senior Marketing Manager, BC (2016–2019). Two ADC roles plus solid tumor marketing make Helga a fit for questions on the lifecycle of ADC products in oncology.
Is this you? Claim your profile and get paid for calls.
Katie Pansegrau, MBA
LinkedInExperience: Senior Director of Marketing · AstraZeneca
Katie Pansegrau's AstraZeneca titles are Senior Director of Marketing since 2026, Marketing Director since 2024, Associate Marketing Director (2023–2024), Marketing Manager (2022–2023) and District Sales Manager (2019–2022). A district sales manager before moving into marketing, Katie fits questions on how brand plans land with field sales teams.
Is this you? Claim your profile and get paid for calls.
Laura Gately, MBA
LinkedInExperience: Senior Director of Marketing, ADHD Brand Lead · Otsuka Pharmaceutical Companies (U.S.)
Laura Gately is Senior Director of Marketing, ADHD Brand Lead at Otsuka Pharmaceutical Companies (U.S.) (since 2025), after Director, HCP Marketing Centanafadine Launch Lead there (2024–2025). Laura was Senior Vice President Commercialization (2022–2024) and Marketing Subject Matter Expert Consultant (2019–2022) at Herspiegel, and Global Franchise Lead, Senior Director of Marketing at Integra LifeSciences (2017–2019). The launch lead and ADHD brand titles fit questions on launching an ADHD therapy through HCP marketing.
Is this you? Claim your profile and get paid for calls.
Megan Mullevey
LinkedInExperience: Global Oncology Marketing Director Individualized Neoantigen Therapy · Merck
Megan Mullevey holds two current Merck titles, Global Oncology Marketing Director Individualized Neoantigen Therapy since 2024 and Global Oncology Marketing Director since 2022, and was Global Marketing Director Oncology (2021–2022), U.S. Marketing Director Vaccines (2020–2022) and Associate Director of Marketing (2017–2020) there. Megan describes strategy development within Merck's vaccine organization, so questions on marketing new oncology modalities and vaccines fit.
Is this you? Claim your profile and get paid for calls.
Oksana Pavlenko, MBA
LinkedInExperience: Head of Marketing Biologics Europe · Dr. Reddy's Laboratories
Oksana Pavlenko is Head of Marketing Biologics Europe at Dr. Reddy's Laboratories (since 2025). At Sandoz, Oksana was Marketing Director Cardiovascular & Metabolics Region Europe (2022–2025), Global LCM Immunology Rotation, Biosimilars, Global Marketing & Access (2024), Marketing Director Rx, Biosimilars & Specialty (2020–2022) and Cardiovascular & Diabetes Launch Lead, Europe (2021–2022). Biosimilar and biologics launches across Europe fit Oksana, who also lists market access among focus areas.
Is this you? Claim your profile and get paid for calls.
Choose the right perspective
For oncology, start with Megan Mullevey, Delphine Sengun, Hannah Bogardus or Helga Lu; for neuropsychiatry and ADHD, Carolyn Hobbs or Laura Gately. Chris Morrison suits US-to-global brand questions, Denise Barrett Quigley payer and rare disease work, Oksana Pavlenko biosimilars in Europe, and Katie Pansegrau the link between brand plans and field sales.
Questions to take into the conversation
- 01How far before approval do you start shaping HCP awareness, and what is allowed in that window?
- 02How do payer coverage decisions change the launch plan in the first year?
- 03Which early prescribing or refill signals tell you a launch is on track?
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.